These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1014 related items for PubMed ID: 25871621
1. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression. Dudley B, Brand RE, Thull D, Bahary N, Nikiforova MN, Pai RK. Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621 [Abstract] [Full Text] [Related]
3. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome. Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM. Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759 [Abstract] [Full Text] [Related]
4. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome. Berginc G, Bracko M, Ravnik-Glavac M, Glavac D. Fam Cancer; 2009 Jun; 8(4):421-9. PubMed ID: 19526325 [Abstract] [Full Text] [Related]
5. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome. Dillon JL, Gonzalez JL, DeMars L, Bloch KJ, Tafe LJ. Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668 [Abstract] [Full Text] [Related]
6. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D. J Clin Oncol; 2015 Dec 20; 33(36):4301-8. PubMed ID: 26552419 [Abstract] [Full Text] [Related]
10. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. Najdawi F, Crook A, Maidens J, McEvoy C, Fellowes A, Pickett J, Ho M, Nevell D, McIlroy K, Sheen A, Sioson L, Ahadi M, Turchini J, Clarkson A, Hogg R, Valmadre S, Gard G, Dooley SJ, Scott RJ, Fox SB, Field M, Gill AJ. Pathology; 2017 Aug 20; 49(5):457-464. PubMed ID: 28669579 [Abstract] [Full Text] [Related]
14. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Halvarsson B, Lindblom A, Rambech E, Lagerstedt K, Nilbert M. Fam Cancer; 2006 Nov 20; 5(4):353-8. PubMed ID: 16817031 [Abstract] [Full Text] [Related]
15. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry. Mills AM, Sloan EA, Thomas M, Modesitt SC, Stoler MH, Atkins KA, Moskaluk CA. Am J Surg Pathol; 2016 Feb 20; 40(2):155-65. PubMed ID: 26523542 [Abstract] [Full Text] [Related]